Analysts Offer Predictions for AnaptysBio FY2025 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB) – Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for shares of AnaptysBio in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will post earnings of ($1.11) per share for the year, down from their previous estimate of $0.66. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q4 2025 earnings at $1.03 EPS, FY2026 earnings at ($2.21) EPS, FY2027 earnings at ($1.58) EPS, FY2028 earnings at $5.18 EPS and FY2029 earnings at $3.11 EPS.

Several other research firms have also weighed in on ANAB. Barclays started coverage on AnaptysBio in a research note on Monday, October 13th. They issued an “overweight” rating and a $78.00 target price on the stock. JPMorgan Chase & Co. lifted their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, October 8th. Wedbush increased their target price on shares of AnaptysBio from $45.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Finally, Wells Fargo & Company boosted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.30.

AnaptysBio Stock Up 6.1%

NASDAQ:ANAB opened at $38.20 on Friday. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $40.96. The stock’s fifty day simple moving average is $28.43 and its 200-day simple moving average is $24.55. The firm has a market capitalization of $1.06 billion, a P/E ratio of -13.55 and a beta of 0.16.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%.

Institutional Investors Weigh In On AnaptysBio

Several large investors have recently made changes to their positions in ANAB. US Bancorp DE raised its holdings in shares of AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 979 shares during the period. Bessemer Group Inc. raised its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the period. Tower Research Capital LLC TRC raised its stake in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the period. Osaic Holdings Inc. lifted its position in shares of AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares during the last quarter. Finally, Brooklyn Investment Group boosted its stake in shares of AnaptysBio by 1,779.9% during the 1st quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 6,034 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.